Elanco Reports $1.371 Billion Revenue in Q1 2026, 15% Increase Year-Over-Year

Elanco Animal Health Incorporated reported a revenue of $1.371 billion for the first quarter of 2026, marking a 15% increase from $1.193 billion in the same period of 2025. The company's gross profit also rose to $785 million, up from $684 million, maintaining a gross margin percentage of 57.3%. However, net income decreased to $57 million, down 15% from $67 million year-over-year, with earnings per share at $0.11 compared to $0.14 in the prior year. The decline in net income was attributed to increased expenses in interest, restructuring, and other special charges, which rose significantly during the quarter.

In terms of operational developments, Elanco's revenue growth was driven by both its pet health and farm animal segments. Pet health revenue increased by 12% to $710 million, while farm animal revenue surged by 18% to $642 million, supported by higher volumes and pricing across all species. The company also reported a notable increase in marketing, selling, and administrative expenses, which rose by 12% to $381 million, reflecting strategic investments in product launches and higher compensation costs.

Elanco has made significant strides in its strategic initiatives, including the acquisition of AHV International B.V., completed on April 30, 2026. This acquisition is expected to enhance Elanco's product portfolio in farm animal health, particularly in cattle, and is anticipated to contribute modestly to revenue in 2026, with a more substantial impact expected in 2027. The company also continues to focus on product innovation, with recent launches such as Zenrelia and Credelio Quattro, which have been well-received in various markets.

The company’s balance sheet as of March 31, 2026, showed total assets of $13.222 billion, a slight decrease from $13.358 billion at the end of 2025. Cash and cash equivalents were reported at $428 million, down from $545 million, while total liabilities decreased to $6.722 billion from $6.811 billion. Elanco's long-term debt stood at $3.918 billion, with the company maintaining compliance with all debt covenants. Looking ahead, Elanco anticipates continued revenue growth driven by its product pipeline and strategic acquisitions, although it remains cautious of macroeconomic factors that could impact its operations.